Somnivera

Explore the latest insights on Somnivera and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Somnivera’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

METiS TechBio Partners with Eli Lilly on AI‑Driven Lipid Nanoparticle Delivery – Up to USD 1.1 Billion in Milestones for Tissue‑Specific LNP Discovery
CompanyDeals

METiS TechBio Partners with Eli Lilly on AI‑Driven Lipid Nanoparticle Delivery – Up to USD 1.1 Billion in Milestones for Tissue‑Specific LNP Discovery

METiS TechBio (HKG: 7666), an innovative AI drug delivery company, announced a strategic collaboration with Eli Lilly and Company (NYSE: LLY) focused on the research and discovery of novel lipid…

Sanofi Breaks Ground on Next‑Generation Insulin Manufacturing Facility at Frankfurt BioCampus – Full API Production Planned for 2032

Sanofi Breaks Ground on Next‑Generation Insulin Manufacturing Facility at Frankfurt BioCampus – Full API Production Planned for 2032

Hansoh Pharma Strikes Second ADC Licensing Deal with Roche – USD 400 Million Upfront, Over USD 15 Billion in Potential Milestones

Hansoh Pharma Strikes Second ADC Licensing Deal with Roche – USD 400 Million Upfront, Over USD 15 Billion in Potential Milestones

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value
CompanyDeals

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value